Xempritolimod is under clinical development by INtRON Biotechnology and currently in Phase I for Oral Mucositis. According to GlobalData, Phase I drugs for Oral Mucositis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Xempritolimod LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Xempritolimod (KMRC-011) is under development for the treatment of radiation toxicity (radiation sickness, acute radiation syndrome), graft versus host disease. The drug candidate is administered by intramuscular route. It acts by targeting toll-like receptor (TLR) 5.
INtRON Biotechnology overview
iNtRON Biotechnology (Intron Bio) is a drug development company. The company develops biotechnology and genetic engineering, which can be used to treat human diseases. Its technologies include endolysin, bacteriophage, biofilm and anti-cancer drug. The company’s endolysin technology is an antibiotic substance that destroys the cell walls of bacteria. Its the Moralbuster New Testament that can brings the dying to life. The company also develops infectious disease drugs. It conducts research and development for developing new drugs to treat various human diseases. The company has operations in Seongnam, Seoul and Daejeon, South Korea. Intron Bio is headquartered in Seongnam, South Korea.
For a complete picture of Xempritolimod’s drug-specific PTSR and LoA scores, buy the report here.